REGENERON PHARMACEUTICALS, INC. Legal Fees
REGENERON PHARMACEUTICALS, INC. (REGN) had Legal Fees of $10.50 million as of 2018-06-25, per its 10-Q filed 2018-11-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2018-11-06
- 2018-06-25: Legal Fees $10.50M.
| Period end | Legal Fees |
|---|---|
| 2018-06-25 | $10.50M 10-Q · filed 2018-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |